Medical Education Session: Distinguishing ATTR and AL Amyloidosis for Australian Clinicians
By
Nicole Bart, MD, PhD, M Hasib Sidiqi, MD, PhD, Elyn Montgomery, PhD, RN
Summary
This article appears to be an introductory or promotional piece for a medical education session on distinguishing transthyretin (ATTR) amyloidosis from light-chain (AL) amyloidosis, aimed at Australian physicians. It lists the moderator and faculty members involved, including specialists in cardiology, hematology, and nursing from Australian institutions. The content is extremely brief (196 words) and primarily consists of speaker credentials rather than substantive medical guidance.
Source
Twitter / XMedical Education Session: Distinguishing ATTR and AL Amyloidosis for Australian Cliniciansmdsc.peKey quotes
· 1 pulledHow well are you distinguishing transthyretin (ATTR) and light-chain amyloidosis (AL) in your practice?
You might also wanna read
Cryo-EM structures of ALECT2 filaments from human renal biopsies
Untitled
https://doi.org/10.1126/science.aeb6987
Once a death sentence, cardiac amyloidosis is finally treatable
Monash University study finds copper-delivering drug Cu(ATSM) reduces Alzheimer's proteins and improves memory in lab tests
Monash University researchers have discovered that a copper-delivering drug called Cu(ATSM) significantly reduces toxic Alzheimer's proteins
monash.edu·9d ago
TAAP-2: Advancing Research on Age-Related Macular Degeneration in Asia
The article discusses the Translational Asian Age-related Macular Degeneration Programme Phase 2 (TAAP-2), a research initiative addressing
scientia.global·2d agoComments
Sign in to join the conversation.
No comments yet. Be the first.